Arcturus Therapeutics Holdings Inc. (ARCT) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
ARCT's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
ARCT Revenue Analysis (2013–2024)
As of March 1, 2026, Arcturus Therapeutics Holdings Inc. (ARCT) generated trailing twelve-month (TTM) revenue of $92.0 million, reflecting significant decline in growth of -55.8% year-over-year. The most recent quarter (Q3 2025) recorded $17.2 million in revenue, down 30.0% sequentially.
Looking at the longer-term picture, ARCT's 5-year compound annual growth rate (CAGR) stands at +46.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $205.8 million in 2022.
Revenue diversification analysis shows ARCT's business is primarily driven by Collaboration Revenue (91%), and Grant (9%). With over half of revenue concentrated in Collaboration Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+65.2% YoY), IONS (+33.8% YoY), and ARWR (+4081.8% YoY), ARCT has underperformed the peer group in terms of revenue growth. Compare ARCT vs ALNY →
Peer Comparison
Compare ARCT's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ARCTCurrent | $92M | -55.8% | +46.1% | -69.1% | |
| ALNY | $3.7B | +65.2% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
| BEAM | $140M | +120.0% | +466.3% | -274.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $138.4M | -12.3% | $138.4M | 100.0% | $-95,669,000 | -69.1% |
| 2023 | $157.7M | -23.3% | $157.7M | 100.0% | $-78,205,000 | -49.6% |
| 2022 | $205.8M | +1564.8% | $205.8M | 100.0% | $12.2M | 5.9% |
| 2021 | $12.4M | +29.6% | $12.4M | 100.0% | $-202,852,000 | -1641.3% |
| 2020 | $9.5M | -54.1% | $-46,407,000 | -486.5% | $-71,524,000 | -749.8% |
| 2019 | $20.8M | +32.0% | $20.8M | 100.0% | $-25,513,000 | -122.7% |
| 2018 | $15.8M | +21.2% | $-1,229,000 | -7.8% | $-21,811,000 | -138.5% |
| 2017 | $13.0M | -36.2% | $12.6M | 96.8% | $-10,492,000 | -80.7% |
| 2016 | $20.4M | +232.1% | $20.1M | 98.6% | $-25,167,000 | -123.5% |
| 2015 | $6.1M | - | $6.1M | 99.2% | $-19,698,000 | -320.9% |
See ARCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARCT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ARCT vs AGIO
See how ARCT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ARCT's revenue growth accelerating or slowing?
ARCT revenue declined -55.8% year-over-year, contrasting with the 5-year CAGR of +46.1%. TTM revenue fell to $92M. This reverses the prior growth trend.
What is ARCT's long-term revenue growth rate?
Arcturus Therapeutics Holdings Inc.'s 5-year revenue CAGR of +46.1% reflects the variable expansion pattern. Current YoY growth of -55.8% is below this long-term average.
How is ARCT's revenue distributed by segment?
ARCT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.